DK1865976T3 - Anvendelse af natriuretiske peptider til behandling af hjertesvigt - Google Patents

Anvendelse af natriuretiske peptider til behandling af hjertesvigt

Info

Publication number
DK1865976T3
DK1865976T3 DK06749753.7T DK06749753T DK1865976T3 DK 1865976 T3 DK1865976 T3 DK 1865976T3 DK 06749753 T DK06749753 T DK 06749753T DK 1865976 T3 DK1865976 T3 DK 1865976T3
Authority
DK
Denmark
Prior art keywords
treatment
heart failure
natriuretic peptides
natriuretic
peptides
Prior art date
Application number
DK06749753.7T
Other languages
English (en)
Inventor
Markus Meyer
Wolf-Georg Forssmann
Klaus Dohler
Veselin Mitrovic
Hartmut Luss
Original Assignee
Cardiopep Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiopep Pharma Gmbh filed Critical Cardiopep Pharma Gmbh
Application granted granted Critical
Publication of DK1865976T3 publication Critical patent/DK1865976T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK06749753.7T 2005-04-07 2006-04-07 Anvendelse af natriuretiske peptider til behandling af hjertesvigt DK1865976T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66978605P 2005-04-07 2005-04-07
US66975105P 2005-04-08 2005-04-08
US73258505P 2005-11-01 2005-11-01
PCT/US2006/013471 WO2006110743A1 (en) 2005-04-07 2006-04-07 Use of natriuretic peptide for treating heart failure

Publications (1)

Publication Number Publication Date
DK1865976T3 true DK1865976T3 (da) 2012-07-23

Family

ID=37087353

Family Applications (2)

Application Number Title Priority Date Filing Date
DK06749753.7T DK1865976T3 (da) 2005-04-07 2006-04-07 Anvendelse af natriuretiske peptider til behandling af hjertesvigt
DK12156696.2T DK2510942T3 (da) 2005-04-07 2006-04-07 Anvendelse af natriuretiske peptider til behandling af hjertesvigt

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12156696.2T DK2510942T3 (da) 2005-04-07 2006-04-07 Anvendelse af natriuretiske peptider til behandling af hjertesvigt

Country Status (10)

Country Link
US (5) US7732406B2 (da)
EP (2) EP2510942B1 (da)
CY (1) CY1113183T1 (da)
DK (2) DK1865976T3 (da)
ES (2) ES2392892T3 (da)
HU (1) HUE026231T2 (da)
PL (2) PL1865976T3 (da)
PT (2) PT1865976E (da)
SI (1) SI2510942T1 (da)
WO (1) WO2006110743A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005235635B2 (en) 2004-04-21 2010-11-18 Alexion Pharmaceuticals, Inc. Bone delivery conjugates and method of using same to target proteins to bone
SI2510942T1 (sl) 2005-04-07 2016-01-29 Cardiorentis Ag Uporaba natriuretskega peptida za zdravljenje srčne odpovedi
US7606617B2 (en) * 2006-01-31 2009-10-20 Cardiac Pacemakers, Inc. Urinalysis for the early detection of and recovery from worsening heart failure
US20080181903A1 (en) * 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region
EP2171053B1 (en) 2007-07-20 2014-04-23 Mayo Foundation for Medical Education and Research Natriuretic polypeptides
EP2078530A1 (en) * 2008-01-08 2009-07-15 Pharis Biotec GmbH Use of natriuretic peptides for treating angioedema syndromes
WO2009034134A2 (en) * 2007-09-11 2009-03-19 Pharis Biotec Gmbh Use of natriuretic peptides for treating angioedema syndromes
EP2341942A1 (en) 2008-09-19 2011-07-13 Nektar Therapeutics Polymer conjugates of therapeutic peptides
EP2547356A1 (en) * 2010-03-15 2013-01-23 Wolf-Georg Forssmann Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound
AU2011350066A1 (en) 2010-12-27 2013-07-11 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
US20120277155A1 (en) * 2011-02-25 2012-11-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
US20150038418A1 (en) * 2011-07-27 2015-02-05 Medtronic, Inc. Natriuretic peptide compositions and methods of preparation
KR20140059249A (ko) 2011-08-30 2014-05-15 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 나트륨이뇨 폴리펩티드
EP2750697A4 (en) 2011-09-02 2015-03-25 Medtronic Inc CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US20140213519A1 (en) * 2013-01-25 2014-07-31 Cardiorentis Ltd. Methods of treating cardiovascular indications
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
US11352612B2 (en) 2015-08-17 2022-06-07 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
JP2019513711A (ja) 2016-04-01 2019-05-30 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
WO2018102397A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
AU2018243320A1 (en) 2017-03-31 2019-10-10 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (HPP) in adults and adolescents
CN109838289B (zh) * 2017-11-27 2022-03-15 罗伯特·博世有限公司 尿素水溶液喷射系统的回抽过程监测系统和方法
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
WO2021183928A1 (en) * 2020-03-13 2021-09-16 Mayo Foundation For Medical Education And Research Assessing and treating acute decompensated heart failure
WO2022029499A1 (en) * 2020-08-06 2022-02-10 Ads Aiphia Development Services Ag Methods of treating refractory ascites

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346953A1 (de) 1983-12-24 1985-08-14 Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung
AU614738B2 (en) 1987-03-02 1991-09-12 Forssmann, Prof. Dr. Med Wolf-Georg New cardiodilatin fragment, process for preparing same and use thereof
US5449751A (en) 1987-03-02 1995-09-12 Pharma Bissendorf Peptide Gmbh Cardiodilatin fragment, process for preparing same and use thereof
US5461142A (en) 1987-11-07 1995-10-24 Pharma Bissendorf Peptide Gmbh Phosphorylated derivatives of cardiodilatin/ANF peptides
US5166191A (en) 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
DE4216133A1 (de) 1992-05-15 1993-11-18 Bissendorf Peptide Gmbh Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
ATE226960T1 (de) 1994-06-02 2002-11-15 Forssmann Wolf Georg Verfahren zur herstellung von cardiodilatin- fragmenten, hochgereinigte cardiodilatin- fragmente und zwischenprodukte zu deren herstellung
US5741776A (en) 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
AU6820898A (en) 1997-04-04 1998-10-30 Novo Nordisk A/S Natriuretic peptide derivatives
DE19951471A1 (de) 1999-10-26 2001-05-03 Forssmann Wolf Georg Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen
US6831084B1 (en) 1999-11-12 2004-12-14 Wyeth Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-HT1A activity
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
EP1326627A4 (en) 2000-10-04 2004-06-16 Molecular Medicine Res Inst METHODS OF MODULATING APOPTOSIS BY ADMINISTERING RELAXIN AGONISTS OR ANTAGONISTS
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20050113286A1 (en) 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US20040063630A1 (en) 2002-03-18 2004-04-01 Scios, Inc. Treatment of congestive heart failure with natriuretic peptide and a diuretic
ATE459370T1 (de) 2002-11-26 2010-03-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
US20060008415A1 (en) 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
US8067464B2 (en) 2004-10-04 2011-11-29 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
EP1855688A4 (en) 2005-02-24 2011-09-14 Nicox Sa NON-STAINED OXIDE DIURETIC COMPOUNDS, COMPOSITIONS AND USE PROCESSES
SI2510942T1 (sl) 2005-04-07 2016-01-29 Cardiorentis Ag Uporaba natriuretskega peptida za zdravljenje srčne odpovedi
WO2008073448A2 (en) 2006-12-12 2008-06-19 Amylin Pharmaceuticals, Inc. Pharmaceutical formulations and methods for making the same
US20080181903A1 (en) 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region
KR20100057641A (ko) 2007-09-11 2010-05-31 몬도바이오테크 래보래토리즈 아게 인터메딘 ４７ 및 ５３ 펩티드의 치료적 용도
WO2009034134A2 (en) 2007-09-11 2009-03-19 Pharis Biotec Gmbh Use of natriuretic peptides for treating angioedema syndromes
US20090163421A1 (en) 2007-12-19 2009-06-25 Ekr Therapeutics, Inc. Room Temperature Stable, Lyophilized Natriuretic Peptide Formulations
WO2009086126A2 (en) 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
WO2010048308A2 (en) 2008-10-24 2010-04-29 Deborah Dickey Natriuretic polypeptides
US9090695B2 (en) 2008-12-03 2015-07-28 Morphosys Ag Antibodies for guanylyl cyclase receptors
EP2413969A4 (en) 2009-03-30 2012-09-05 Boehringer Ingelheim Int FUSION PROTEINS WITH DOG FC ELEMENTS
US20110065676A1 (en) 2009-06-24 2011-03-17 Schering Corporation Combination therapies comprising par1 antagonists with nar agonists
US20110014180A1 (en) 2009-07-16 2011-01-20 Masafumi Koide Preparations for tissue restoration containing atrial diuretic hormone and family molecules as active ingredients; method of restoring tissue using the preparation; agents for growing, restoring, promoting growth of hair and agents for promoting restoration of skin tissue and cardiac muscle tissue containing atrial diuretic hormone family molecules as active ingredients; method of growing, restoring, promoting growth of hair by using the agents; and method of promoting restoration of skin tissue and cardiac muscle tissue
WO2011038066A2 (en) 2009-09-25 2011-03-31 Alcon Research, Ltd. Novel npr-b agonists
JP5893561B2 (ja) 2009-09-25 2016-03-23 シャイア・オーファン・セラピーズ・ゲーエムベーハーＳｈｉｒｅ Ｏｒｐｈａｎ Ｔｈｅｒａｐｉｅｓ ＧｍｂＨ 新規ｎｐｒ−ｂアゴニスト
EP2547356A1 (en) 2010-03-15 2013-01-23 Wolf-Georg Forssmann Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound
US20120052097A1 (en) 2010-08-20 2012-03-01 Cerulean Pharma Inc. Therapeutic peptide-polymer conjugates, particles, compositions, and related methods

Also Published As

Publication number Publication date
HUE026231T2 (en) 2016-06-28
US7732406B2 (en) 2010-06-08
PT1865976E (pt) 2012-08-03
EP1865976A4 (en) 2010-09-01
US20110257099A1 (en) 2011-10-20
CY1113183T1 (el) 2016-04-13
EP1865976B1 (en) 2012-05-23
SI2510942T1 (sl) 2016-01-29
US20150224174A1 (en) 2015-08-13
WO2006110743A1 (en) 2006-10-19
EP2510942A1 (en) 2012-10-17
ES2392892T3 (es) 2012-12-14
PT2510942E (pt) 2015-12-28
US20140287999A1 (en) 2014-09-25
PL1865976T3 (pl) 2012-11-30
EP1865976A1 (en) 2007-12-19
US9358271B2 (en) 2016-06-07
US8710006B2 (en) 2014-04-29
EP2510942B1 (en) 2015-09-02
ES2554713T3 (es) 2015-12-22
PL2510942T3 (pl) 2016-02-29
US9023794B2 (en) 2015-05-05
DK2510942T3 (da) 2015-12-14
US20160324931A1 (en) 2016-11-10
US20060264376A1 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
DK1865976T3 (da) Anvendelse af natriuretiske peptider til behandling af hjertesvigt
DK1685834T3 (da) Anvendelse af pinolensyre til behandling af obesitet
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK3424932T3 (da) Bronophthalider til terapeutisk anvendelse
DK2298237T3 (da) Hjerteprotese
DK1948176T3 (da) Diarylurinstoffer til behandling af pulmonær hypertension
DE602006008227D1 (de) Endoluminale Prothese
DK1937633T3 (da) Biphenyloxyeddikesyrederivater til behandling af respiratoriske sygdomme
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
DE502005003383D1 (de) Intrakardiale blutpumpe
DE602006016150D1 (de) Vorbeugung von krankheiten bei kaiserschnitt-babies
DE602005026030D1 (de) Blutdruckmessgerät
DE602005024846D1 (de) Blutdialysator
DK2035447T3 (da) Polypeptid
DE602006010883D1 (de) Korrekturflüssigkeiten
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
DK3332789T3 (da) Cladribinkur til behandling af multipel sklerose
DK1968623T3 (da) Bacteriocin-inducer-peptider
DE502004010641D1 (de) Atemschutzmaske
DK2323686T3 (da) Adiponectin til behandling af lungesygdom
ITBO20040642A1 (it) Giunto vascolare
DE502004009940D1 (de) Piezoelektrischer aktor
DE102005060186B8 (de) Treppengängiger Rollstuhl
FR2880798B1 (fr) Fauteuil roulant
FI6726U1 (fi) Hieromalaite